Core Points - Three unprofitable companies, He Yuan Bio, Xi'an Yicai, and Bibet, have successfully listed on the Sci-Tech Innovation Board, marking a significant step in facilitating the listing path for unprofitable hard-tech enterprises [1] - The stock prices of the three companies surged significantly on their debut, with He Yuan Bio rising by 213.5%, Xi'an Yicai by 198.7%, and Bibet by 74.4%, all with a turnover rate exceeding 70% [1] Company Summaries - He Yuan Bio is an innovative biopharmaceutical company with a leading global plant bioreactor technology platform and has established a proprietary rice endosperm cell bioreactor expression system [1] - Xi'an Yicai focuses on the research, production, and sales of 12-inch silicon wafers [1] - Bibet is a biopharmaceutical company with its core product BEBT-908 already approved for market, while other products are still in the research and development phase [1] Industry Developments - The establishment of the Sci-Tech Growth Layer aims to support technology companies that have significant breakthroughs, broad commercial prospects, and substantial ongoing R&D investments, even if they are currently unprofitable [2] - The Sci-Tech Board has seen a 37.79% year-on-year revenue growth among companies in the growth layer for the first half of the year, with a significant reduction in losses amounting to 71.23 billion [2] - Since the launch of the Sci-Tech Board, 54 unprofitable companies have been supported for listing, with 22 of them achieving profitability post-listing, averaging four companies per year [2]

值得一提的是，根据"科创板八条"的相关试点安排，禾元生物也是首家采用网下发行差异化限售与配售 安排的公司。禾元生物公告显示，其网下整体限售比例不低于40%，对投资者报价设置了3档差异化限 售档位，申购最高限售档位投资者的配售比例不低于最低限售档位的9倍。 北京商报讯(记者丁宁)9月22日晚间，禾元生物(688765)披露发行安排及初步询价公告等，正式启动发行 工作。 招股书显示，禾元生物是一家创新型生物医药企业，拥有全球领先的植物生物反应器技术平台。据悉， 禾元生物是重启科创板第五套标准后的首家过会并取得注册批文的企业，也是科创成长层新注册企业中 首家启动发行工作的企业。 ...